EGFR and colorectal carcinoma: The major clinical trials evaluating ICIs, bevacizumab, and anti‐EGFR monoclonal antibodies as first‐line therapies in advanced CRC are summarized in Table 3 [98, 99, 100, 101, 102, 103, 104, 105].